Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Effecting a 1-for-10 Reverse Stock Split

NEW YORK (GenomeWeb) – Interpace will effect a 1-for-10 reverse stock split in a bid to keep its shares listed on the Nasdaq, the company announced after the close of the market on Wednesday.

The reverse split, which takes effect at the start of trading on Thursday, is being effected in order to meet a requirement calling for a minimum bid price of $1 per share in order to continue listing on the Nasdaq Capital Market. Nasdaq had warned the company of the possible delisting in January, then issued another warning to Interpace in November, saying the firm failed to meet another listing requirement of a minimum $2.5 million in stockholders' equity.

Interpace said that it anticipates a Nasdaq hearing and cannot assure continued listing on the exchange will occur, however. Interpace's shares closed on Wednesday at $.75 per share.

The company's shareholders approved the split in August, and Interpace's board subsequently approved the ratio. After the reverse split, the number of Interpace's common stock outstanding will be reduced to about 2 million shares from 20.2 million shares. 

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.